AFfirm™ Lamin B1 Mouse Monoclonal Antibody - #BF8009

(9)   (4)  
Product: Lamin B1 Mouse Monoclonal Antibody
Catalog: BF8009
Description: Mouse monoclonal antibody to Lamin B1
Application: WB
Reactivity: Human, Mouse, Rat
Mol.Wt.: 66kD; 66kD(Calculated).
Uniprot: P20700

View similar products>>

   Size Price Inventory
 50ul $150 In stock
 100ul $250 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Mouse
Application:
WB 1:500-1:3000
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Clonality:
Monoclonal [AFfirm8009]
Specificity:
Lamin B1 Mouse Monoclonal Antibody detects endogenous levels of total Lamin B1.
Conjugate:
Unconjugated.
Purification:
Affinity-chromatography.
Storage:
Mouse IgG1 in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

ADLD; lamin B1; Lamin-B1; LMN; LMN2; LMNB; Lmnb1; LMNB1_HUMAN; MGC111419; OTTHUMP00000159218;

Immunogens

Immunogen:

A synthesized peptide derived from human Lamin B1.

Uniprot:

P20700(LMNB1_HUMAN) >>Visit HPA database.

Gene(ID):
LMNB1(4001)
Sequence:
MATATPVPPRMGSRAGGPTTPLSPTRLSRLQEKEELRELNDRLAVYIDKVRSLETENSALQLQVTEREEVRGRELTGLKALYETELADARRALDDTARERAKLQIELGKCKAEHDQLLLNYAKKESDLNGAQIKLREYEAALNSKDAALATALGDKKSLEGDLEDLKDQIAQLEASLAAAKKQLADETLLKVDLENRCQSLTEDLEFRKSMYEEEINETRRKHETRLVEVDSGRQIEYEYKLAQALHEMREQHDAQVRLYKEELEQTYHAKLENARLSSEMNTSTVNSAREELMESRMRIESLSSQLSNLQKESRACLERIQELEDLLAKEKDNSRRMLTDKEREMAEIRDQMQQQLNDYEQLLDVKLALDMEISAYRKLLEGEEERLKLSPSPSSRVTVSRASSSRSVRTTRGKRKRVDVEESEASSSVSISHSASATGNVCIEEIDVDGKFIRLKNTSEQDQPMGGWEMIRKIGDTSVSYKYTSRYVLKAGQTVTIWAANAGVTASPPTDLIWKNQNSWGTGEDVKVILKNSQGEEVAQRSTVFKTTIPEEEEEEEEAAGVVVEEELFHQQGTPRASNRSCAIM

PTMs - P20700 As Substrate

Site PTM Type Enzyme
A2 Acetylation
T3 Phosphorylation
T5 Phosphorylation
R10 Methylation
S13 Phosphorylation
R14 Methylation
T19 Phosphorylation
T20 Phosphorylation
S23 Phosphorylation P06493 (CDK1)
T25 Phosphorylation
S28 Phosphorylation
K33 Acetylation
K33 Ubiquitination
R42 Methylation
Y46 Phosphorylation
K49 Acetylation
K49 Ubiquitination
S58 Phosphorylation
K79 Acetylation
K79 Ubiquitination
Y82 Phosphorylation
T84 Phosphorylation
K102 Acetylation
K102 Sumoylation
K102 Ubiquitination
K109 Ubiquitination
K111 Acetylation
K111 Ubiquitination
K123 Acetylation
K123 Ubiquitination
K124 Ubiquitination
S126 Phosphorylation
K134 Acetylation
K134 Ubiquitination
Y138 Phosphorylation
S144 Phosphorylation
K145 Ubiquitination
K156 Acetylation
K156 Ubiquitination
K157 Acetylation
K157 Ubiquitination
S158 Phosphorylation
K167 Ubiquitination
K181 Acetylation
K181 Ubiquitination
K182 Ubiquitination
R197 Methylation
C198 S-Nitrosylation
S200 Phosphorylation
K209 Acetylation
K209 Ubiquitination
S210 Phosphorylation
Y212 Phosphorylation
K222 Ubiquitination
S232 Phosphorylation
Y238 Phosphorylation
K241 Sumoylation
K241 Ubiquitination
R250 Methylation
K261 Sumoylation
K261 Ubiquitination
T267 Phosphorylation
Y268 Phosphorylation
K271 Acetylation
K271 Ubiquitination
S278 Phosphorylation
S279 Phosphorylation
T283 Phosphorylation
S284 Phosphorylation
T285 Phosphorylation
S288 Phosphorylation
R297 Methylation
R299 Methylation
S302 Phosphorylation
S304 Phosphorylation
S305 Phosphorylation
K312 Acetylation
K312 Ubiquitination
K330 Ubiquitination
T340 Phosphorylation
K342 Ubiquitination
Y360 Phosphorylation
S375 Phosphorylation
Y377 Phosphorylation
K379 Acetylation
K379 Sumoylation
K379 Ubiquitination
R387 Methylation
K389 Sumoylation
K389 Ubiquitination
S391 Phosphorylation
S393 Phosphorylation P06493 (CDK1)
S395 Phosphorylation P05771 (PRKCB)
S396 Phosphorylation
T399 Phosphorylation
S401 Phosphorylation
S404 Phosphorylation
S405 Phosphorylation P05771 (PRKCB)
S406 Phosphorylation
S408 Phosphorylation
T411 Phosphorylation
T412 Phosphorylation
K457 Ubiquitination
S460 Phosphorylation
K474 Ubiquitination
S479 Phosphorylation
S481 Phosphorylation
K483 Acetylation
K483 Ubiquitination
K528 Ubiquitination
K532 Acetylation
K532 Ubiquitination
S534 Phosphorylation
K547 Ubiquitination
T575 Phosphorylation
S579 Phosphorylation

Research Backgrounds

Function:

Lamins are components of the nuclear lamina, a fibrous layer on the nucleoplasmic side of the inner nuclear membrane, which is thought to provide a framework for the nuclear envelope and may also interact with chromatin.

PTMs:

B-type lamins undergo a series of modifications, such as farnesylation and phosphorylation. Increased phosphorylation of the lamins occurs before envelope disintegration and probably plays a role in regulating lamin associations.

Subcellular Location:

Nucleus inner membrane>Lipid-anchor>Nucleoplasmic side.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Subunit Structure:

Homodimer. Interacts with lamin-associated polypeptides IA, IB and 2. Interacts with SPAG4 and SEPT12.

Family&Domains:

Belongs to the intermediate filament family.

Research Fields

· Cellular Processes > Cell growth and death > Apoptosis.   (View pathway)

References

1). ANXA1 promotes tumor immune evasion by binding PARP1 and upregulating Stat3-induced expression of PD-L1 in multiple cancers. Cancer Immunology Research (PubMed: 37566399) [IF=10.1]
2). Honokiol suppresses the aberrant interactions between renal resident macrophages and tubular epithelial cells in lupus nephritis through the NLRP3/IL-33/ST2 axis. Cell Death & Disease (PubMed: 36859530) [IF=9.0]

Application: WB    Species: Mouse    Sample:

Fig. 5: Effects of Honokiol (HNK) on the renal levels of the NLRP3 inflammasome and the ST2 and NF-κB proteins in MpJ/lpr mice.
3). Improving hyperglycemic effect of FGF-21 is associated with alleviating inflammatory state in diabetes. International Immunopharmacology (PubMed: 29414665) [IF=5.6]
4). FGF-21 Elevated IL-10 Production to Correct LPS-Induced Inflammation. INFLAMMATION (PubMed: 29427162) [IF=5.1]
5). Astragaloside IV mitigates cerebral ischaemia-reperfusion injury via inhibition of P62/Keap1/Nrf2 pathway-mediated ferroptosis. European Journal of Pharmacology (PubMed: 36758783) [IF=5.0]
6). Silymarin protects against acrylamide-induced neurotoxicity via Nrf2 signalling in PC12 cells. FOOD AND CHEMICAL TOXICOLOGY (PubMed: 28137608) [IF=4.3]

Application: WB    Species: rat    Sample: PC12 cells

7). Interaction with tumor‑associated macrophages promotes PRL‑3‑induced invasion of colorectal cancer cells via MAPK pathway‑induced EMT and NF‑κB signaling‑induced angiogenesis. ONCOLOGY REPORTS (PubMed: 30864736) [IF=4.2]

Application: WB    Species: mouse    Sample: LoVo‑P and HT29‑NC cells

Figure 6.| PRL‑3 promotes angiogenesis by activating the NF‑κB pathway.(D) NF‑κB pathway activation was examined by western blot analysis. *P<0.05. PRL‑3, phosphatase of regenerating liver‑3; VEGF, vascular endothelial growth factor; TAM, tumor‑associated macrophage; NC, negative control; LoVo‑P, LoVo PRL‑3 overexpression; p, phosphor; IKKα, nuclear factor κ‑B kinase subunit α; AREG, amphiregulin; b‑NGF, β nerve growth factor; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; GM‑CSF, granulocyte‑macrophage colony‑stimulating factor; IGFBP2, insulin‑like growth factor‑binding protein 2; NT‑4, neurotrophin‑4; VEGFR2, vascular endothelial growth factor receptor 2; IκBα, NF‑κB inhibitor α.
8). Echinatin mitigates sevoflurane-induced hippocampal neurotoxicity and cognitive deficits through mitigation of iron overload and oxidative stress. PHARMACEUTICAL BIOLOGY (PubMed: 36205592) [IF=3.8]
9). Edaravone Ameliorates Cerebral Ischemia–Reperfusion Injury by Downregulating Ferroptosis via the Nrf2/FPN Pathway in Rats. BIOLOGICAL & PHARMACEUTICAL BULLETIN (PubMed: 36047195) [IF=2.0]

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.